Cover Image
Market Research Report
Product code 
1034341

Global Acute Migraine Drugs Market - 2021-2028

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Acute Migraine Drugs Market - 2021-2028
Published: October 27, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • Description
  • Table of Contents

Market Overview

The global acute migraine drugs market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Migraine is a neurological disorder that includes headaches, nausea, inability to smell, increased sensitivity to sound and light, and numbness. These headaches occur on one side of the head with different durations and intensities. Acute Migraine Drugs are given to terminate the migraine attacks.

Market Dynamics

Increasing prevalence of migraines is driving the market growth

A migraine is a headache that causes severe throbbing pain, normally on one side of the head. Its often accompanied by nausea, vomiting, and severe sensitivity to light and sound, and migraine attacks can last for hours to days. The pain can be so sharp that it interferes with your daily activities. Moreover, it affects children, teenagers, and adults and can grow through four stages: prodrome, aura, attack, and post-drome. According to the article (Research gate), not everyone who has migraines goes through all stages (Research gate), published on April 8, 2021. The prevalence of migraines was 18.2% among females and 6.5% among males-approximately 23% of households contained at least one member suffering from migraines. Migraine prevalence is higher in whites than in blacks and was inversely related to household income. Thus, a rise in the prevalence of migraine cases leads to increased demand for migraine treatment drugs.

Launch of the CGRP antagonist by the market players is driving the acute migrane drugs market growth

Allergan is under license to Merck & Co. has developed Ubrogepant (Ubrelvy), an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that received its first global approval in the USA for the acute treatment of migraine (± aura) in adults on December 2019. Also, the recommended dosage of oral ubrogepant is 50 mg or 100 mg taken as needed without regard to food. Hence, with increasing launch of new drugs for the treatment of migraine is expected to drive the growth of market over the forecast period.

Side effects of acute migraine drugs are likely to hamper the the acute migrane drugs market growth

In October 2019, the U.S. Food and Drug Administration (FDA) approved the first-in-class "ditan"-lasmiditan 50 mg and 100 mg tablets. For acute treatment of migraine with or without aura in adults. Lasmiditan is a 5-HT agonist with an over 440 times more potent binding affinity for 5-HT1F than 5-HT1B and 5-HT1D receptors and which potently inhibits markers of electrical stimulation of the trigeminal ganglion. In addition, 50-200 mg of the dose is recommended depending on the pain intensity. It is not recommended to take more than one dose in a day or drive vehicles up to 8 h after taking the drug; if taken, then it leads to most common side effects, including dizziness, fatigue, paresthesia, and sedation. Therefore, besides its benefits for treating acute migraines, few side effects are expected to hamper the market growth.

COVID-19 Impact Analysis

The coronavirus disease 2019 (COVID-19) pandemic has caused overwhelming challenges in healthcare worldwide. Migraine is one of the commonest and extremely disabling chronic neurological diseases in the world. During the pandemic and lockdown, migraine patients face a huge problem getting utmost care because of difficulty in admittance, forced social isolation, and encountering a health system that is getting overwhelmed. Moreover, in the absence of therapeutic procedures, other preventive therapies such as self-injectable monoclonal antibodies, neuromodulation devices and oral corticosteroids are used. The patients must be protected by reducing their visits to the clinics and emergency departments.

Moreover, paradoxically multiple triggers are in operation, which is likely to increase their headache frequency. Hence, physicians should be aware of the game's new rules in handling migraines during the pandemic so that these patients get maximum treatment and care and don't feel left out. The pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the market will undergo impetus during the forecast period.

Segment Analysis

On the basis of type of drugs, Triptans held the largest market share in 2020

The triptans segment accounted for the largest market share in 2020. It is an effective first-line treatment for moderate to severe migraine, and several triptans are available with different pharmacokinetics and routes of administration. As 5-hydroxytryptamine receptor agonists, they are pharmacologically specific for migraines and can be used in adequate doses with few major adverse effects.

Moreover, for migraines with aura, evidence suggests that the best results are achieved by taking the triptan at the onset of pain rather than the onset of aura. However, taking a triptan during a typical aura seems to be safe. Accordingly, a meta-analysis of the effectiveness of the seven available triptans (almotriptan [Axert], eletriptan [Relpax], frovatriptan [Frova], naratriptan [Amerge], rizatriptan [Maxalt], sumatriptan [Imitrex], and zolmitriptan [Zomig]) found that standard doses provided headache relief at two hours in 42% to 76% of patients and complete pain relief at two hours in 18% to 50%. In addition, for headache relief at two hours, standard-dose triptans alone performed better than ergot alkaloids, equal to or better than NSAIDs and acetaminophen, and equal to or slightly worse than combination therapies (triptan plus NSAID or acetaminophen). For example, sumatriptan is the most extensively studied triptan. Its effectiveness varies by dose and route of administration. All triptans have strong evidence of effectiveness, but few head-to-head comparisons have been performed. The strongest evidence and most favorable outcomes are reported for subcutaneous sumatriptan, rizatriptan orally disintegrating tablets (Maxalt Mlt), zolmitriptan orally disintegrating tablets (Zomig Zmt), and eletriptan tablets. Therefore, sumatriptan as a subcutaneous 6-mg injection has the most favorable NNT for complete pain relief at two hours.

Geographical Analysis

North America region holds the largest market share in the global acute migraine drugs market.

North America accounted for the largest revenue share in 2020. The growth of this region is attributed to the high prevalence of acute migraine, increased usage of CGRP based therapies, increasing adoption of novel therapeutics, and large target populations in the U.S. are the factors expected to boost the market in the forecast period. For instance, according to the Journal of Pain Research, published on 20 April 2021, a migraine with brainstem aura (MBA) accompanied by disorders of consciousness (DOC) is a rare subtype of migraine. The pathophysiology of MBA with DOC has not been elucidated yet. Some patients have a family history of migraines, and women are more affected than men. The aura symptoms are diverse; however, the clinical manifestations are more complicated when MBA is combined with DOC. The first-generation CGRP receptor antagonists, gepants, were effective for the abortive treatment of migraines. However, they were not fully developed because of hepatotoxicity. Ubrogepant, also known as MK-1602, is an oral, small-molecule CGRP receptor antagonist for acute migraine treatment. A study found that 2 hours after ubrogepant administration, the patient's headache and aura symptoms were relieved. Unlike other gepants, ubrogepant has no hepatotoxicity at therapeutic doses.

In addition, the ACHIEVE II Randomized Clinical Trial study found that both 50-mg and 25-mg doses can significantly relieve migraines. However, only a 50 mg dose helped to reduce the aura. A Phase III, randomized, 52-week extension trial further confirmed the safety of long-term intermittent use of ubrogepant 50 and 100 mg doses. Short-term use of ubrogepant is not related to an increased risk for adverse events. The time course of ubrogepant efficacy was demonstrated to 48 h, providing evidence of the long-lasting effect. Therefore for the subjective feelings of patients, the potential benefits of ubrogepant could improve patient-centered satisfaction. Thus, the North American region holds the largest market share in the forecast period from the above statements.

Competitive Landscape

The acute migraine drugs market is highly competitive with presence of several global companies. Some of the key players which are contributing to the growth of the market include GSK, Teva, Pfizer, Novartis, Sun Pharma, Merck and Johnson and Johnson. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the acute migraine drugs market globally.

Acute Migraine Drugs Market Key Companies to Watch

Sun Pharmaceutical Industries Limited:

Overview:

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. Moreover, the company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It provides APIs such as warfarin, carbamazepine, etodolac, clorazepate, anti-cancers, steroids, peptides, sex hormones, and controlled substances. Additionally, the company has a global presence in over 150 countries across branded and generic segments. It is backed by strong R&D capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets and capsules.

Product Portfolio:

Sun Pharmaceutical Industries Limited is into continuous manufacturing of acute migraine drugs including Sumatriptan Succinate Tablets (sue-muh-TRIP-tan SUX-in-ate) and Sumatriptan Injection, USP (sue-muh-TRIP-tan).

Why Purchase the Report?

  • Visualize the composition of the acute migraine drugs market segmentation by type, route of administration, end user and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in acute migraine drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of acute migraine drugs market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global acute migraine drugs market report would provide an access to an approx. 46 market data table, 47 figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Acute Migraine Drugs Market - By Type

  • Triptans
  • NSAIDs
  • Others

Global Acute Migraine Drugs Market - By Route of Administration

  • Oral
  • Injectable
  • Nasal sprays
  • Others

Global Acute Migraine Drugs Market - By End user

  • Hospital Pharmacies
  • Drug Stores

Global Acute Migraine Drugs Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Product Code: DMPH4243

Table of Contents

1. Global Acute Migraine Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Acute Migraine Drugs Market - Market Definition and Overview

3. Global Acute Migraine Drugs Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by End user
  • 3.4. Market Snippet by Region

4. Global Acute Migraine Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of migraines
      • 4.1.1.2. Launch of the CGRP antagonist by the market players
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects of acute migraine drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Acute Migraine Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. PEST Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. Global Acute Migraine Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Acute Migraine Drugs Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Triptans*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. NSAIDs
  • 7.4. Others

8. Global Acute Migraine Drugs Market - By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Injectable
  • 8.4. Nasal sprays
  • 8.5. Others

9. Global Acute Migraine Drugs Market - By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user Segment
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Drug Stores

10. Global Acute Migraine Drugs Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Global Acute Migraine Drugs Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch
  • 11.5. List of Company with disruptive technology
  • 11.6. List of Start Up Companies

12. Global Acute Migraine Drugs Market- Company Profiles

  • 12.1. Sun Pharma*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GSK
  • 12.3. Teva
  • 12.4. Pfizer
  • 12.5. Novartis
  • 12.6. Johnson and Johnson
  • 12.7. Merck (LIST NOT EXHAUSTIVE)

13. Global Acute Migraine Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us
  • 13.3. Contact Us